You are here

Article Text

Article menu
Download PDFPDF
Education in Heart
Antithrombotic therapy for patients with chronic coronary syndromes

https://doi.org/10.1136/heartjnl-2020-316914

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors WAEP drafted the article under supervision of RFS, who edited and approved the final version.

    • Funding WAEP is supported by British Heart Foundation Clinical Research Training Fellowship no. FS/18/49/33752.

    • Competing interests RFS reports institutional research grants/support from AstraZeneca, GlyCardial Diagnostics and Thromboserin; consultancy fees from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb/Pfizer, Cytosorbents, GlyCardial Diagnostics, Haemonetics, Portola and Thromboserin; and honoraria from AstraZeneca, Bayer, Bristol Myers Squibb/Pfizer and Medscape.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Commissioned; externally peer reviewed.

    • Author note References which include a * are considered to be key references.